Follow me to the promised land :-)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah, i took my losses already. 5K down but I made well over 12K in AMRN so it all good.
I'll keep watch AMRN though. Still have Acrhor data NDA and other stuff.
bad day for longs.
yeah, not good for AMRN bc the people who brought for buyout are dumping the stock.
Holding 2000 shares and down 5K+ AH already.
I can't believe that NCE have been delay until now. Sorry, I don't have a good answer. I really didn't expect NCE to be delay on Nov.
Bc of the delay and uncertainty, I'm not playing options and only owning stocks bc I have a lot of time on hand.
GL bud
long 4000 shares right now but will take profit when I see fit.
AMRN: chart starting to look bullish. Movement before mid Dec NCE decision finally!
I've been well, thanks bud. How are yourself? Hope all is well.
I'm holding 2000 shares as of now. Used to hold 4K but i've been trading in and out do to the volatility from NCE.
GLTU
I believe NCE is delay again. See it on twitter
Nice, patents for Marine out of the way.
I'm definitely not selling here. Even without NCE, ANCHOR approval should bring the company to $18 PT. I just planning on how to add to this dip and wondering where it will bottom. GL
Do u know if this price target is a 12 months price target? So, would $15 PT account for ANCHOR approval too?Thanks
My pick for this week is IND. They will be playing the JAC. Thanks. have a good weekend!
I pick NYG this week. they play against TB on Sunday. Thank u
Could see a break out above $35 in the coming weeks. With the Fed. help of course.
thank u for sharing. that was a good read.
Inbox is correct. Thanks
hi, I pick HOU for the first week. Thank you for the invite!
Nice, AMRN move on patent news
News: Eaton Scientific Systems Confirms Acquisition and Status of Tropine 3 Patent Pending Non-Hormonal Treatment of Hot Flashes in...
Eaton Scientific Systems, Ltd. ("Eaton Scientific" or the "Company"), a wholly owned subsidiary of Pristine Solutions, Inc. (OTCQB: PRTN) is pleased to announce that it has completed the acquisition of pending patent USPTO #60/719,756, an invention that provides a Method for Relieving Climacteric Symptoms ("Hot Flashes"). According to the 2000 US Census, there are over 37.5 million American women between the ages of 40-59 that are in the age range for pre-menopause, menopause and peri-menopause that have the potential for experiencing hot flash symptoms.
"The Company believes that its Patent Pending Application covering a novel indication of the FDA approved drug homatropine, known as Tropine 3, has substantial strategic value in the rapidly growing women's healthcare market, particularly the menopausal symptom management market," stated Michael Borkowski, CEO and President of Eaton Scientific. "Safe and effective non-hormonal menopausal symptom management is a very high priority issue for many women. Eaton Scientific is well positioned to benefit from this dramatic global market opportunity, as the Company continues to develop market awareness and prepares to introduce Tropine 3 to a much larger audience in the near future."
Eaton Scientific makes the following Claims as part of its USPTO Application #60/719,756 Patent Pending Application, an invention that provides a Method for Relieving Climacteric Symptoms ("Hot Flashes").
The climacteric is defined as the syndrome of endocrine, somatic and psychological changes occurring at the termination of the reproductive period in the female. According to the Greene Climacteric scale (Greene (1998) Maturitas 29:25-31), there are 21 common symptoms associated with a woman's climacteric stage, namely heart beating quickly or strongly, feeling tense or nervous, difficulty in sleeping, excitability, attacks of panic, difficulty in concentrating, feeling tired or lacking in energy, loss of interest in most things, feeling unhappy or depressed, crying spells, irritability, feeling dizzy or faint, pressure or tightness in head or body, parts of the body feel numb or tingling, headaches, muscle and joint pains, loss of feeling in hands and feet, breathing difficulties, hot flushes, sweating at night, and loss of interest in sex. Other symptoms commonly experienced in climacteric women include urinary frequency and urgency, palpitations, and anxiety.
It has now been found that anticholinergic agents, such as homatropine, alleviate hot flushes in peri-menopausal and post-menopausal women. In general, anticholinergic agents work by modulating the activity of muscarinic receptors, which mediate a variety of cellular responses. For example, muscarinic receptors in smooth muscle regulate cardiac contractions, gut motility and bronchial constriction, whereas muscarinic receptors in exocrine glands stimulate gastric acid secretion, salivation and lacrimation. Muscarinic receptors also are found in the superior cervical ganglion, cerebral cortex, the striatum, the hippocampus, thalamus, and brainstem.
Eaton Scientific and its management believe that its USPTO Patent Pending Application is a vital part of its business thesis and as such the company is committed to updating its shareholders to any significant developments in its Application.
About Pristine Solutions, Inc.Pristine Solutions, Inc., through its wholly-owned subsidiary company, Eaton Scientific Systems, Ltd., holds the intellectual property and global marketing rights to Tropine 3, a patent pending novel indication of an existing FDA approved drug for the non-hormonal treatment of hot flashes in pre-menopausal, pari-menopausal, and post-menopausal women.
Forward-Looking Statements/DisclaimerInformation in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pristine Solutions' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Pristine Solutions' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Pristine Solutions herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Pristine Solutions disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
SOURCE Eaton Scientific Systems, Ltd.
the link is not working properly. Could u repost. thanks
Question for number d.? do APS sent out a warning? what did you meant by number d? TIA
did you get an email similar to this one? TIA
Hi Everyone,
Please note the following:
We have a new email address thanks to new management and to insure that you receive your favorite newsletter inside your inbox it is imperative that you immediately add us to your 'safe-sender' list.
By doing so you'll ensure you're ready to receive the brand new pick that will be announced shortly!
Tell your friends who are not signed up to go ahead and sign up right now. You can forward this email to your contact list to facilitate the process.
Fund your brokerage account now so that can buy the new pick as soon as it's announced!
Speaking of announcements if you would like to receive the pick before everyone else there is an exclusive service that has been created for members who wish to possibly gain an extra 50% + on top of the usual gains .
They will announce all the picks before everyone else and you can be one of the first people on the planet to get in before the crowds. You can just go to www.PremiumStockReport.com to take a peek at this phenomenal service.
Happy Trading!
Your PennyPic Editor.
link is broken, please post another link. thanks
ken, where do one go to sign up to receive email from Bedford group? TIA
nice trade, good buying opportunity if you still believe in patents, NCE, and Buyout potentials. I sold 2/3 of my position and brought them back during the day too.
did not expect AMRN to drop 10%
yeah, got filled 1000 shares at 13.50.
sold all my position except for 1000 shares. crazy morning. I'll buy back later today
good morning kei, crazy pre-market. AMRN is getting a few upgrade and price target increased this morning
Leerink OP, PT increased from $25 to $27
Jefferies OP, PT increased from $26 to $28
we are now positive PM wow
what a worried premarket. $15.20 just hit
Wow, didn't see this kind of pre-market coming. It move up to 14.80 now
Thank you. Vascepa got all 5 labels they wanted with possible 2013 indication for dyslipidemia (ANCHOR). FYI: Lovaza trial failed for mixed dyslipidemia. Awesome job there. The company believes it can shift share of Lovaza to Vascepa and expand its own market.
Other catalysts to look forward too:
1) At the end of the CC, Joe mention the company expect positive patent news for the MARINE patent in the coming weeks.
2) NCE status still in active dialogue with FDA. expect decision mid Aug. Company expect at least 3 years exclusivity and positive on 5 years exclusivity.
3) Company believe at least 4 out of the 5 Marine patents will be in the Orange book.
4) No more formal meeting with the FDA is required for ANCHOR NDA. Company is free to file NDA when REDUCE-IT is on its way.
5) Buyout is prefer over partnership and buyout is very much on the table. If not, the company feel confident they can commercialize own their own with collaboration.
Actually this post summed up most things I wanted to say:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=77914375
Good Night
AMRN: Gonna be more than that IMO, partnership and buyout is on table. Good CC.. excited for us longs.
Good night all
AMRN: AMR101 approval for TG >= 500mg/dL
Sorry, the table is mess up
Approval Based on Positive Results From MARINE Study
Conference Call Scheduled for Today, July 26th at 7:00 p.m. EDT
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the U.S. Food and Drug Administration (FDA) has approved VascepaTM (icosapent ethyl) capsules (formerly known as AMR101) as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (TG greater than or equal to 500mg/dL) hypertriglyceridemia (very high triglycerides). Amarin submitted the New Drug Application (NDA) for the use of Vascepa in this indication in September 2011.
"FDA approval of Vascepa represents the introduction of an important new treatment option for patients with severe hypertriglyceridemia. In Amarin's MARINE clinical trial, Vascepa demonstrated a statistically significant placebo-adjusted reduction in levels of triglycerides without elevation in levels of LDL-C, commonly referred to as 'bad cholesterol,'" stated Joseph Zakrzewski, Chairman and CEO of Amarin. "Amarin continues to anticipate commercial launch of Vascepa early in the first quarter of 2013, and we continue to consider three potential paths for the marketing and sale of the product: an acquisition of Amarin, a strategic collaboration, or self-commercialization, the latter of which could include third-party support. We are now focused on continued commercial preparations for Vascepa which includes, but is not limited to, finalizing the introduction of Vascepa to managed care plans to gain formulary access, building-up inventory levels and coordinating other pre-launch marketing activities."
The efficacy and safety of Vascepa were assessed in Amarin's MARINE clinical trial, a randomized, placebo-controlled, double-blind, parallel-group study of adult patients with very high fasting triglyceride levels, between 500 mg/dL and 2000 mg/dL. At baseline, 25% of patients were on concomitant statin therapy, 28% were diabetics, and 39% of patients had TG levels greater than 750 mg/dL. Patients treated for 12 weeks with the 4 gram dose of Vascepa demonstrated a statistically significant placebo-adjusted median triglyceride reduction of 33% (p<0.001), and did not show an increase in LDL-C levels relative to placebo. Vascepa 4 grams per day also showed statistically significant placebo-adjusted median reductions from baseline in non-HDL-C (total cholesterol less "good cholesterol") of 18%, Total Cholesterol (TC) of 16%, Very Low Density Lipoprotein Cholesterol (VLDL-C) of 29%, and apolipoprotein B (Apo B) of 9%.
The most commonly reported adverse reaction (incidence >2% and greater than placebo) in Vascepa treated patients was arthralgia (joint pain) (2.3% for Vascepa vs. 1.0% for placebo).
The following table shows the changes in major lipoprotein and lipid parameters for the treatment groups:
Median Baseline and Percent Change from Baseline in Lipid Parameters in Patients with Severe (greater than or equal to 500 mg/dL) Hypertriglyceridemia
Vascepa 4 g/day Placebo
N=76 N=75
Parameter Baseline % Change Baseline % Change Difference (95%
Confidence
Interval)
TG (mg/dL) 680 -27 703 +10 -33* (-47, -22)
LDL-C (mg/dL) 91 -5 86 -3 -2 (-13, +8)
Non-HDL-C (mg/dL) 225 -8 229 +8 -18 (-25, -11)
TC (mg/dL) 254 -7 256 +8 -16 (-22, -11)
HDL-C (mg/dL) 27 -4 27 0 -4 (-9, +2)
VLDL-C (mg/dL) 123 -20 124 +14 -29** (-43, -14)
Apo B (mg/dL) 121 -4 118 +4 -9**(-14, -3)
% Change= Median Percent Change from Baseline
Difference= Median of [Vascepa % Change – Placebo % Change] (Hodges-Lehmann Estimate)
p-values from Wilcoxon rank-sum test
*p-value < 0.001 (primary efficacy endpoint)
**p-value < 0.05 (key secondary efficacy endpoints determined to be statistically significant according to the pre-specified multiple comparison procedure)
Apo B = apolipoprotein B; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; non-HDL-C = non-high-density lipoprotein cholesterol; TC = total cholesterol; TG = triglyceride; VLDL-C = very-low-density lipoprotein cholesterol
Note: All endpoints in the above table for MARINE were statistically significant with the exception of HDL-C.
Amarin has made significant progress in its efforts to expand the patent protection for Vascepa in the United States to at least 2030 with seven patent applications either issued, allowed or in progressed states of prosecution and over 25 additional U.S. applications pending. Amarin is awaiting a decision from FDA as to whether Vascepa will be granted five-year new chemical entity (NCE) or three-year new product marketing exclusivity under the provisions of the Hatch-Waxman amendments to the Federal Food, Drug, and Cosmetic Act. Typically, FDA's determination on the exclusivity of approved products is made public through the posting on FDA's website in the Orange Book. This typically occurs mid-month following the month of an NDA approval.
About VascepaTM (icosapent ethyl) capsules
VascepaTM (icosapent ethyl) capsules, known in scientific literature as AMR101, is a patented, ultra-pure omega-3 fatty acid product, comprising not less than 96% EPA in a 1 gram capsule.
IMPORTANT PRESCRIBING INFORMATION
Vascepa™ (icosapent ethyl) is indicated for use in the United States as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (greater than or equal to500 mg/dL) hypertriglyceridemia.
The effect of Vascepa on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.
The effect of Vascepa on cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia levels has not been determined.
The daily dose of Vascepa is 4 grams administered orally. Patients should engage in appropriate nutritional intake and physical activity before receiving Vascepa, which should continue during treatment.
FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM
IMPORTANT SAFETY INFORMATION
Attempts should be made to control any medical problems such as diabetes mellitus, hypothyroidism and alcohol intake that may contribute to the lipid abnormalities. Lipid levels should be consistently abnormal before initiating Vascepa.
Medications affecting coagulation (e.g., anti-platelet agents) should be monitored periodically.
In patients with hepatic impairment, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels should be monitored periodically during therapy. Use with caution in patients with known hypersensitivity to fish and/or shellfish.
The most commonly reported adverse reaction (incidence >2% and greater than placebo) in Vascepa treated patients was arthralgia (joint pain) (2.3% for Vascepa vs. 1.0% for placebo).
About Severe (greater than or equal to 500 mg/dL) Hypertriglyceridemia
Severe hypertriglyceridemia refers to a condition in which patients have very high levels of triglycerides (greater than or equal to 500 mg/dL) in the bloodstream. Amarin estimates that approximately 4 million people in the United States have severe hypertriglyceridemia. According to The American Heart Association Scientific Statement on Triglycerides and Cardiovascular Disease (2011), triglycerides provide important information as a marker associated with the risk for heart disease and stroke, especially when an individual also has low high-density lipoprotein cholesterol, or HDL-C (often referred to as "good" cholesterol), and elevated levels of LDL-C (often referred to as "bad" cholesterol). The effect of Vascepa on cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined.
Conference call for investors
Amarin will host a conference call and webcast for investors, today at 7:00 p.m. EDT to discuss FDA's approval of Vascepa. The conference call will be webcast live and a link to the webcast may be accessed from the "Events & Presentations" page on the Amarin corporate website at www.amarincorp.com.
To listen to the live call on the telephone, dial 1-877-407-8033 (United States and Canada) or 1-201-689-8033 (International). The conference call ID number is 397905. A replay of the call will be available for 30 days by dialing 1-877-660-6853 (United States and Canada) or 1-201-612-7415 (International), account number 286, conference ID 397905.
About Amarin
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. VascepaTM (icosapent ethyl) is Amarin's first FDA approved product. For more information about Vascepa visit www.vascepa.com. Amarin plans to separately seek approval for the use of Vascepa in the treatment of patients with high triglyceride levels who are also on statin therapy for elevated LDL-C levels, the population studied in Amarin's ANCHOR trial, after Amarin's REDUCE-IT cardiovascular outcomes trial is substantially underway. Like Amarin's MARINE study, each of Amarin's ANCHOR and REDUCE-IT studies is the subject of a Special Protocol Assessment (SPA) agreement with the FDA. For more information about Amarin visit www.amarincorp.com.
The Amarin Corporation plc logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13817
Forward-looking statements
This press release contains forward-looking statements, including statements about the efficacy, safety and therapeutic benefits of Vascepa, clinical trial results, the clinical importance of certain biomarkers and the impact of Vascepa on such biomarkers, the timing of a commercial launch of Vascepa, the potential additional indications for which FDA marketing approval of Vascepa may be sought and the commercial potential of Vascepa, the potential for an acquisition of Amarin or a strategic collaboration with a third party for the commercialization of Vascepa, the timing and outcome of FDA's review determination of whether Vascepa should be granted new chemical entity or new product marketing exclusivity, the status of patent applications currently under review by the United States Patent and Trademark Office, the coverage and expected expiration dates of those patent applications and issued patents and the ability of Amarin to protect the commercial potential of Vascepa. In particular there can be no assurance that Vascepa will be awarded five-year new chemical entity or three-year new product marketing exclusivity and the FDA may take longer than expected to reach any such determination. Amarin's patent portfolio directed to the formulation and uses of Vascepa is still evolving and some patent applications may not issue prior to commercial launch, if ever. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: uncertainties associated generally with the commercial success of new pharmaceutical products, such as Vascepa; Amarin's ability to negotiate and execute a successful acquisition of Amarin or a strategic collaboration with a third party for the commercialization of Vascepa; Amarin's lack of experience with commercializing pharmaceutical products; risks associated with preparations associated with a commercial launch; the risk that FDA may not grant new chemical entity or new product marketing exclusivity to Vascepa; the risk that FDA may not reach a determination with respect to these matters on the timetable that we expect; the risk that patent applications may not result in issued patents, and that issued patents may not prevent competitors from competing with Vascepa; the risk that competitors may challenge the validity, enforceability or both the validity and enforceability of our patents or seek to design products around our issued patent claims and gain marketing approval for generic versions of Vascepa or branded competitive products based on new clinical studies; and the risk that trade secrets may not be maintained and that circumstances that create manufacturing barriers to entry may not last. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in the "Risk Factors" section of Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise except as required by law.
Amarin's product candidates are in various stages of development and are not available for sale or use outside of approved clinical trials, except as it relates to the FDA approval announced herein. This press release is intended for communication with investors. Nothing in this press release should be construed as marketing the use of such product candidates.
CONTACT: Investor contact information:
Stephen D. Schultz
Senior Director, Investor Relations and
Corporate Communications
Amarin Corporation
In U.S.: +1 (908) 719-1315
Direct: +1 (908) 326-1323
investor.relations@amarincorp.com
Gitanjali Jain Ogawa
The Trout Group
In U.S.: +1 (646) 378-2949 (office)
+1 (650) 269-7523 (mobile)
Gogawa@troutgroup.com
Media contact information:
David Schull or Martina Schwarzkopf, Ph.D.
Russo Partners
In U.S.: +1 (212) 845-4271 or +1 (212) 845-4292 (office)
+1 (347) 591-8785 (mobile)
david.schull@russopartnersllc.com
martina.schwarzkopf@russopartnersllc.com
company logo
http://ih.advfn.com/p.php?pid=nmona&article=53613889
Thanks for the awesome summary!
i do believe there is more news then just FDA approval but I may be wrong. I'm an optimistic person
Cheers my friend, I'm holding for partnership/buyout news in the coming months. But u you stick with your plan.
Congratz all longs more new pending IMO, big news hopefully.
I'm on my 4th beer, cheers
read the post after the first one. That poster got AMRN mess up with GLUU
GL too all AMRN longs!!!
i've seen it on twitter. We will know soon enough. Tmr is AMRN big day.
Looking for managements to tell us more about partnership or buyout after FDA approval.
AMRN is not ARNA. I played ARNA but sold most before and the rest after approval. I do not believe ARNA drug will be profitable enough to justify the PPS.
GLTA, longs
AMRN MKM reaffirm buy rating this morning. PT: $21.50
http://www.jagsreport.com/2012/07/mkm-partners-reaffirms-buy-rating-on-amarin-co-plc-amrn/
Can't wait for next week. Things should really get going for AMRN and its stock price!
hey bud, I'm planning shifting some of my shares to calls since calls got cheaper today and friday expiration on the july. Thinking about taking 1000 shares off the table and buying 20 more Aug 16 calls.
Planning to hold 3000 shares, 20 aug 18 calls, and 20 aug 16 calls through FDA decision.
What is your plan bud?